Comparing the current results to its competitors, Praxis Precision Medicines Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 7.75 %, recorded in the same quarter.
Praxis Precision Medicines Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment characterized by rapid technological and scientific changes. Competitors may obtain regulatory approval ahead of the company or develop therapies that are safer, more advanced, or more effective, potentially affecting the company's ability to market or commercialize its product candidates. Competitors include providers of approved therapies for essential tremor, such as propranolol, and off-label treatments like primidone. Additionally, companies such as SK-Pharma, Xenon Pharmaceuticals, and Biohaven Pharmaceuticals are developing sodium channel blocker or similar ion channel-targeting programs for common epilepsies. Other competitors, including Lundbeck and Stoke Therapeutics, have programs targeting different mechanisms of action, along with approved therapies involving other ion channel blockers. Many competitors possess substantial financial resources and expertise in research and development, regulatory approval, manufacturing, and marketing. Smaller or early-stage companies may also present competition, particularly through mergers, acquisitions, or collaborations with established firms.
January 5, 2024
Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China: Collaboration leverages Tenacia s expertise in central nervous system drug development and commercialization and will address a significant unmet patient needIn an exciting development for the field of precision medicines, Praxis Precision Medicines has recently announced a licensing and collaboration agreement with Tenacia Biotechnology for the distribution of Ulixacaltamide in Greater China. This collaboration is set to leverage Tenacia s expertise in central nervous system drug development and commercialization, and more importantly, it aims to address a significant un...
Publicly Traded Peers of Praxis Precision Medicines Inc
Gain Therapeutics inc Share Performance
-2.75%
Over The Past 5 Days
Gain Therapeutics inc
Profile
Gain Therapeutics inc's business model revolves around using cutting-edge technology and innovative approaches to identify and develop small molecules that can effectively target and treat rare genetic diseases, such as lysosomal storage disorders and CNS-related disorders. They aim to leverage their expertise in computational drug design and protein structure analysis to discover potential drug candidates, which can then be developed and commercialized for therapeutic purposes.
Madrigal Pharmaceuticals Inc's business model is focused on developing and commercializing innovative therapeutic solutions for liver diseases, with a particular emphasis on non-alcoholic steatohepatitis (NASH) and other metabolic diseases. They aim to provide effective treatments to address unmet medical needs and improve patient outcomes in these areas.
Mira Pharmaceuticals Inc's business model is focused on the development and sale of pharmaceutical products, with a particular emphasis on research and innovation in the healthcare industry.
Milestone Pharmaceuticals Inc. is a pharmaceutical company that focuses on developing and commercializing innovative therapies for cardiovascular diseases. Their business model revolves around identifying unmet medical needs in the cardiovascular space and leveraging their expertise in drug development to create novel treatments. By conducting rigorous research, clinical trials, and collaborations, Milestone Pharmaceuticals aims to bring effective and safe medications to market, positively impacting patients' lives.
Sources:
Praxis Precision Medicines Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Praxis Precision Medicines Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
